痤疮药物治疗研究进展

doi:10.35541/cjd.20200615

Abstract

Abstract: 【Abstract】 Some progress has been made in pharmacological treatments for acne in recent years. Several new medications have been proven effective and safe in latest clinical trials, including sarecycline （a novel tetracycline-class antibiotic）, trifarotene （a new fourth-generation retinoid）, clascoterone （the first topical androgen receptor antagonist）, 4% SB204（a nitric oxide-releasing gel）, 4% FMX101 （a topical minocycline foam）, etc. This review summarizes latest advances in drug therapy for acne.

Key words: Acne vulgaris, Drug therapy, Sarecycline, Trifarotene, Minocycline, Dapsone

Peng Ying, Liu Yi. Medications for the treatment of acne[J]. Chinese Journal of Dermatology, 2023, 56(2): 173-176.doi:10.35541/cjd.20200615

References ［34］

［1］	鞠强. 中外痤疮指南药物治疗之亮点［J］. 中华皮肤科杂志, 2017,50（6）:459⁃462. doi: 10.3760/cma.j.issn.0412⁃4030.2017. 06.024.
［2］	Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti⁃acne agents［J］. Arch Dermatol Res, 2019,311（5）:337⁃349. doi: 10.1007/s00403⁃019⁃01908⁃x.
［3］	Zhanel G, Critchley I, Lin LY, et al. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris［J］. Antimicrob Agents Chemother, 2019,63（1）:e01297⁃18. doi: 10.1128/AAC.01297⁃18.
［4］	Moore A, Green LJ, Bruce S, et al. Once⁃daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double⁃blind clinical trials［J］. J Drugs Dermatol, 2018,17（9）:987⁃996.
［5］	Asadi A, Abdi M, Kouhsari E, et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: back to the future［J］. J Glob Antimicrob Resist, 2020,22:161⁃174. doi: 10.1016/j.jgar.2020.01.022.
［6］	Dosik J, Ellman H, Stuart I. Topical minocycline foam 4%: results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation［J］. J Immunotoxicol, 2019,16（1）:133⁃139. doi: 10. 1080/1547691X.2019.1610117.
［7］	Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate⁃to⁃severe acne vulgaris: results of 2 randomized, double⁃blind, phase 3 studies［J］. J Am Acad Dermatol, 2019,80（1）:168⁃177. doi: 10.1016/j.jaad.2018. 08.020.
［8］	Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study［J］. J Am Acad Dermatol, 2020,82（4）:832⁃837. doi: 10.1016/j.jaad.2019.05.078.
［9］	Yin S, Luo J, Qian A, et al. Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity［J］. J Clin Invest, 2013,123（9）:3941⁃3951. doi: 10.1172/JCI66413.
［10］	Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor⁃γ agonist trifarotene［J］. Br J Dermatol, 2018,179（2）:442⁃456. doi: 10.1111/bjd.16719.
［11］	Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne［J］. J Am Acad Dermatol, 2019,80（6）:1691⁃1699. doi: 10.1016/j.jaad.2019.02.044.
［12］	Blume⁃Peytavi U, Fowler J, Kemény L, et al. Long⁃term safety and efficacy of trifarotene 50 μg/g cream, a first⁃in⁃class RAR⁃γ selective topical retinoid, in patients with moderate facial and truncal acne［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:166⁃173. doi: 10.1111/jdv.15794.
［13］	Ju Q, Tao T, Hu T, et al. Sex hormones and acne［J］. Clin Dermatol, 2017,35（2）:130⁃137. doi: 10.1016/j.clindermatol.2016. 10.004.
［14］	Park JH, Bienenfeld A, Orlow SJ, et al. The use of hormonal antiandrogen therapy in female patients with acne: a 10⁃year retrospective Study［J］. Am J Clin Dermatol, 2018,19（3）:449⁃455. doi: 10.1007/s40257⁃018⁃0349⁃6.
［15］	Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17α⁃propionate （clascoterone） is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro［J］. J Drugs Dermatol, 2019,18（5）:412⁃418.
［16］	Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials［J］. JAMA Dermatol, 2020,156（6）:621⁃630. doi: 10.1001/jamadermatol. 2020.0465.
［17］	Eichenfield L, Hebert A, Gold LS, et al. Open⁃label, long⁃term extension study to evaluate the safety of clascoterone （CB⁃03⁃01） cream, 1% twice daily, in patients with acne vulgaris［J］. J Am Acad Dermatol, 2020,83（2）:477⁃485. doi: 10.1016/j.jaad. 2020.04.087.
［18］	Keating GM. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years［J］. Am J Clin Dermatol, 2011,12（6）:407⁃420. doi: 10.2165/11208170⁃000000000⁃00000.
［19］	Seidler EM, Kimball AB. Meta⁃analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne［J］. J Am Acad Dermatol, 2010,63（1）:52⁃62. doi: 10.1016/j.jaad.2009.07.052.
［20］	Amar L, Kircik LH. Treatment of moderate acne vulgaris in fitzpatrick skin type Ⅴ or Ⅵ: efficacy and tolerability of fixed combination clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel［J］. J Drugs Dermatol, 2018,17（10）:1107⁃1112.
［21］	Zouboulis CC, Fischer TC, Wohlrab J, et al. Study of the efficacy, tolerability, and safety of 2 fixed⁃dose combination gels in the management of acne vulgaris［J］. Cutis, 2009,84（4）:223⁃229.
［22］	Weiss J, Stein Gold L, Leoni M, et al. Customized single⁃agent therapy management of severe inflammatory acne: a randomized, double⁃blind, parallel⁃group, controlled study of a new treatment⁃⁃adapalene 0.3%⁃benzoyl peroxide 2.5% gel［J］. J Drugs Dermatol, 2015,14（12）:1427⁃1435.
［23］	Gold MH, Baldwin H, Lin T. Management of comedonal acne vulgaris with fixed⁃combination topical therapy［J］. J Cosmet Dermatol, 2018,17（2）:227⁃231. doi: 10.1111/jocd.12497.
［24］	Ghaoui N, Hanna E, Abbas O, et al. Update on the use of dapsone in dermatology［J］. Int J Dermatol, 2020,59（7）:787⁃795. doi: 10.1111/ijd.14761.
［25］	Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once⁃daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle⁃controlled trials［J］. J Drugs Dermatol, 2016,15（5）:553⁃561.
［26］	Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once⁃daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle⁃controlled trials［J］. J Drugs Dermatol, 2016,15（8）:962⁃969.
［27］	Jarratt MT, Jones TM, Chang⁃Lin JE, et al. Safety and pharmacokinetics of once⁃daily dapsone gel, 7.5% in Patients With Moderate Acne Vulgaris［J］. J Drugs Dermatol, 2016,15（10）:1250⁃1259.
［28］	Yale S, Stefanko N, McCarthy P, et al. Severe methemoglobinemia due to topical dapsone misuse in a teenage girl［J］. Pediatr Dermatol, 2020,37（2）:377⁃378. doi: 10.1111/pde.14080.
［29］	Jones ML, Ganopolsky JG, Labbé A, et al. Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices［J］. Appl Microbiol Biotechnol, 2010,88（2）:401⁃407. doi: 10.1007/s00253⁃010⁃2733⁃x.
［30］	Qin M, Landriscina A, Rosen JM, et al. Nitric oxide⁃releasing nanoparticles prevent propionibacterium acnes⁃induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response［J］. J Invest Dermatol, 2015,135（11）:2723⁃2731. doi: 10.1038/jid. 2015.277.
［31］	Hebert A,Del Rosso J, Rico M, et al.Evaluation of the efficacy, safety and tolerability of SB204 4% once⁃daily in subjects with moderate to severe acne vulgaris treated topically for up to 52 weeks ［R/OL］//American Academy of Dermatology （AAD） Annual Meeting, San Diego, 2018［2020⁃06⁃01］. http: //novan.com/files/3115/1913/6178/SB204_Phase_3_AAD_Latebreaker_Presentation_vf.pdf.
［32］	Melnik BC. Olumacostat glasaretil, a promising topical sebum⁃suppressing agent that affects all major pathogenic factors of acne vulgaris［J］. J Invest Dermatol, 2017,137（7）:1405⁃1408. doi: 10.1016/j.jid.2017.01.026.
［33］	Dermira, Inc. Dermira′s two phase 3 trials evaluating olumacostat glasaretil in patients with acne vulgaris did not meet co⁃ primary endpoints ［EB/OL］. （2018⁃03⁃05）［2020⁃06⁃01］. https://investor.dermira.com/news⁃releases/press⁃release⁃details/2018/Dermiras⁃Two⁃Phase⁃3⁃Trials⁃Evaluating⁃Olumacostat⁃Glasaretil⁃in⁃Patients⁃with⁃Acne⁃Vulgaris⁃Did⁃Not⁃Meet⁃Co⁃Primary⁃Endpoints/default.aspx.
［34］	Valente Duarte De Sousa IC. New and emerging drugs for the treatment of acne vulgaris in adolescents［J］. Expert Opin Pharmacother, 2019,20（8）:1009⁃1024. doi: 10.1080/14656566. 2019.1584182.

[1]	Zhang Hongyan, Li Li, Wang Mingxia, Dong Yinmao, Meng Hong, Yi Fan. Role of probiotics in the treatment of acne [J]. Chinese Journal of Dermatology, 2023, 56(3): 283-285.
[2]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220337-e20220337.
[3]	Sun Jing, Xu Yingnan, Lin Tong, Xue Jinsong. Analysis of clinical treatment outcomes of ocular lesions in 28 cases of severe ocular rosacea [J]. Chinese Journal of Dermatology, 2023, 56(2): 142-145.
[4]	Fan Birao, Chen Xixue, Wang Mingyue. Retrospective analysis of efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of 15 cases of pemphigus erythematosus and 9 cases of pemphigus herpetiformis [J]. Chinese Journal of Dermatology, 2022, 55(8): 676-681.
[5]	Wu Shuhui, Zhu Mingfang, Wei Lu, Zhang Xi, Qin Qiuyan, Wang Chang. Effect of pomegranate peel polyphenols on mTOR/HIF-1α/IL-17 signaling pathway in a rat auriclular model of acne [J]. Chinese Journal of Dermatology, 2022, 55(6): 511-516.
[6]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[7]	Wu Shuhui, Zhu Mingfang, Zhang Xi, Yang Yixuan, Zhang Juanjuan. Effect of milk on sebaceous gland spots and the IGF-1/SREBP-1/ACC-1 signaling pathway in golden hamsters [J]. Chinese Journal of Dermatology, 2022, 55(3): 238-242.
[8]	Chinese Dermatologist Association. Expert consensus on clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of acne vulgaris （2022） [J]. Chinese Journal of Dermatology, 2022, 55(12): 1050-1057.
[9]	Ding Tiantian, Cui Baohong, Mi Shuhong, Zhang Yang, Zheng Hailin, Shi Jihai, Liu Weida. Comparison of drug susceptibility of and drug resistance mutations in fluconazole-resistant Candida albicans strains from superficial and deep infections [J]. Chinese Journal of Dermatology, 2022, 55(10): 874-878.
[10]	Li Jiaqi, Ye Feng, Ju Qiang. Symbiotic homeostasis of Staphylococcus epidermidis is associated with common skin disorders [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210072-e20210072.
[11]	Feng Mengdi, Wang Wenqing. Regulatory roles of transcription factors and receptors in the pathogenesis of acne [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210457-e20210457.
[12]	Laser Cosmetology Group, Medical Aesthetics and Cosmetology Branch of Chinese Medical Association, Cosmetic Laser Group, Chinese Society of Dermatology, Laser Group, Cosmetic and Plastic Surgeon Branch of Chinese Medical Doctor Association. Consensus on treatment of acne scars in China （2021） [J]. Chinese Journal of Dermatology, 2021, 54(9): 747-756.
[13]	Wu Shuhui, Zhu Mingfang, Wei Lu, Zhang Xi, Zhu Yameng. Effect of pomegranate peel polyphenols on sebaceous gland spots and AKT/Sox9 signaling pathway in golden hamsters [J]. Chinese Journal of Dermatology, 2021, 54(8): 705-708.
[14]	Ying Jieya, Xiang Wenzhong, Song Xiuzu. Metabolic syndrome and skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(7): 642-645.
[15]	Lu Gaihui, Li Tao, Liu Xuewei. Effect of benzathine penicillin combined with ceftriaxone on the results of rapid plasma reagin circle card test/toluidine red unheated serum test in the treatment of early syphilis: a meta-analysis [J]. Chinese Journal of Dermatology, 2021, 54(6): 522-526.

Medications for the treatment of acne

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［34］

Related Articles 15

Metrics

Comments

Recommended 10